Save Our Swings

Eric Lefkofsky’s Constant Mission to Improve the Healthcare System

The cost of healthcare has been rising over the past few years, prompting medical researchers to look at the underlying reasons for the continuous rise. Researchers investigating changes in healthcare cost between 1996 and 2013 came up with a conclusion that the higher charges that Americans are experiencing are as a result of specific care that is intense and expensive as opposed to drug or medication prices. Population growth and an increase in the aging population were other factors driving the care cost changes. To be more specific, Americans spent $933 billion in 2013 more than they did in 1996. The researchers opted to break down healthcare cost into specific healthcare spending requirements of various diseases. Top spending drivers differed from one illness to another, for example, diabetes, had different value drivers compared to low back and neck pains.

In the thick and thin of the healthcare wobbles is Eric Lefkofsky who has co-founded a tech company, Tempus, that is working to build the necessary technological infrastructure to standardize and modernize treatment of cancer. Eric Lefkofsky’s venture collects huge amounts of genomic data, and through statistical analysis tools coupled with proprietary algorithms, they unearth opportunities specific to patients enabling physicians to make better and informed treatment decisions. The standardizing of cancer treatment will work in the long run to stabilize health care costs for cancer patients.

Philanthropically, Eric Lefkofsky has donated huge sums of money to charitable causes supporting cancer treatment and research. And in 2006 Eric Lefkofsky teamed up with his wife to establish the Lefkofsky Family Foundation. In its mission, the foundation hopes to support charitable, scientific, and educational organizations and causes across the globe. The foundation avails funds to medical research institutions such as North Shore University Health System in Chicago, Lurie Children’s Memorial Hospital which also hosts Lefkofsky Family Pediatric Intensive Care Unit and the University of Chicago Comer Children’s Hospital. Cancer centers such as American Brain Tumor Association founded by Susan Kramer, Damon Runyon, and Memorial Sloan-Kettering Cancer Center have all been beneficiaries of the Lefkofsky Family Foundation funds. On the global stage, the foundation’s funds causes working to enhance human rights.

To Learn More Click This Link :

Amicus Therapeutics Breakthroughs

Amicus Therapeutics is a well-known biopharmaceutical company that was made public in 2007. The main focus of Amicus Therapeutics is to focus on diseases that are considered rare but have been abandoned by medical science research (Twitter). The main focus they have is on long-abandoned disorders that fall into the category of lysosomal storage disorders. Their goal is to create treatments for the category of disorders that are considered Chaperone-Advanced Replacement Therapy Drugs.


Even though Amicus Therapeutics focuses on a wide range of research, they were noted in 2014 for having the largest catalog of information on small molecule pharmacological chaperones in the medication realm.


In 2014, they did not have any available drugs on the market, but they do have a large number of drugs in the works for the future, and a large number of them are considered to be scientific breakthroughs, even though they are not available yet and are still being perfected.


Currently, Amicus is only a research and breakthrough location. They are not capable of manufacturing the medications themselves. They are reliant on contract manufacturing, which allows them to focus on research as the larger picture.


Medical Research

Research into lysosomal storage disorders is extremely important, especially since it is considered to be a rare category of diseases and companies found researching the disorders difficult so they abandoned all attempts at finding medication, treatment, and a cure.


Amicus Therapeutics has cornered the market in their research and the drugs they are developing offer a lot of promise in the medical world, and not just in lysosomal storage disorder treatment. Their research could open the door to research on diseases that have been left untouched for years, if not decades. The research they have developed can be expanded upon to treat other disorders that are genetically linked to the condition.

More at

Scroll To Top